Sfoglia per Autore
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic
2022 Fu, X.; De Angelis, C.; Schiff, R.
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients
2022 Cuomo, A.; Mercurio, V.; Varricchi, G.; Galdiero, M. R.; Rossi, F. W.; Carannante, A.; Arpino, G.; Formisano, L.; Bianco, R.; Carlomagno, C.; De Angelis, C.; Giuliano, M.; Matano, E.; Picardi, M.; Salvatore, D.; De Vita, F.; Martinelli, E.; Della Corte, C. M.; Morgillo, F.; Orditura, M.; Napolitano, S.; Troiani, T.; Tocchetti, C. G.
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer
2022 Buonaiuto, Roberto; Napolitano, Fabiana; Parola, Sara; De Placido, Pietro; Forestieri, Valeria; Pecoraro, Giovanna; Servetto, Alberto; Formisano, Luigi; Formisano, Pietro; Giuliano, Mario; Arpino, Grazia; De Placido, Sabino; De Angelis, Carmine
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
2022 Bianchini, G.; De Angelis, C.; Licata, L.; Gianni, L.
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
2021 Veeraraghavan, J.; Gutierrez, C.; Sethunath, V.; Mehravaran, S.; Giuliano, M.; Shea, M. J.; Mitchell, T.; Wang, T.; Nanda, S.; Pereira, R.; Davis, R.; Goutsouliak, K.; Qin, L.; De Angelis, C.; Diala, I.; Lalani, A. S.; Nagi, C.; Hilsenbeck, S. G.; Rimawi, M. F.; Osborne, C. K.; Schiff, R.
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054]
2021 De Angelis, C; Bruzzese, D; Bernardo, A; Baldini, E; Leo, L; Fabi, A; Gamucci, T; De Placido, P; Poggio, F; Russo, S; Forestieri, V; Lauria, R; De Santo, I; Caputo, R; Cianniello, D; Michelotti, A; Del Mastro, L; De Laurentiis, M; Giuliano, M; De Placido, S; Arpino, G
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
2021 De Angelis, C; Bruzzese, D; Bernardo, A; Baldini, E; Leo, L; Fabi, A; Gamucci, T; De Placido, P; Poggio, F; Russo, S; Forestieri, V; Lauria, R; De Santo, I; Michelotti, A; Del Mastro, L; De Laurentiis, M; Giuliano, M; De Placido, S; Arpino, G
Brca1/2 ngs somatic testing in clinical practice: a short report
2021 Pepe, F.; Pisapia, P.; Russo, G.; Nacchio, M.; Pallante, P.; Vigliar, E.; De Angelis, C.; Insabato, L.; Bellevicine, C.; De Placido, S.; Troncone, G.; Malapelle, U.
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer
2021 Servetto, A.; Napolitano, F.; De Angelis, C.; De Placido, P.; Giuliano, M.; Arpino, G.; De Placido, S.; Bianco, R.; Formisano, L.
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer
2021 Abdulkareem, N. M.; Bhat, R.; Qin, L.; Vasaikar, S.; Gopinathan, A.; Mitchell, T.; Shea, M. J.; Nanda, S.; Thangavel, H.; Zhang, B.; De Angelis, C.; Schiff, R.; Trivedi, M. V.
Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer
2021 De Angelis, C.; Fu, X.; Cataldo, M. L.; Nardone, A.; Pereira, R.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Sethunath, V.; Wang, T.; Hilsenbeck, S. G.; Benelli, M.; Migliaccio, I.; Guarducci, C.; Malorni, L.; Litchfield, L. M.; Liu, J.; Donaldson, J.; Selenica, P.; Brown, D. N.; Weigelt, B.; Reis-Filho, J. S.; Park, B. H.; Hurvitz, S. A.; Slamon, D. J.; Rimawi, M. F.; Jansen, V. M.; Jeselsohn, R.; Osborne, C. K.; Schiff, R.
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie
2021 De Angelis, Carmine; Nardelli, Carmela; Concolino, Paola; Pagliuca, Martina; Setaro, Mario; De Paolis, Elisa; De Placido, Pietro; Forestieri, Valeria; Scaglione, Giovanni Luca; Ranieri, Annalisa; Lombardo, Barbara; Pastore, Lucio; De Placido, Sabino; Capoluongo, Ettore
Towards personalized treatment for early stage HER2-positive breast cancer
2020 Goutsouliak, K.; Veeraraghavan, J.; Sethunath, V.; De Angelis, C.; Osborne, C. K.; Rimawi, M. F.; Schiff, R.
Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy
2020 Perri, F.; Ionna, F.; Longo, F.; Della Vittoria Scarpati, G.; De Angelis, C.; Ottaiano, A.; Botti, G.; Caponigro, F.
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance
2020 Bi, M.; Zhang, Z.; Jiang, Y. -Z.; Xue, P.; Wang, H.; Lai, Z.; Fu, X.; De Angelis, C.; Gong, Y.; Gao, Z.; Ruan, J.; Jin, V. X.; Marangoni, E.; Montaudon, E.; Glass, C. K.; Li, W.; Huang, T. H. -M.; Shao, Z. -M.; Schiff, R.; Chen, L.; Liu, Z.
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer
2020 Rimawi, Mothaffar F; Niravath, Polly; Wang, Tao; Rexer, Brent N; Forero, Andres; Wolff, Antonio C; Nanda, Rita; Storniolo, Anna M; Krop, Ian; Goetz, Matthew P; Nangia, Julie R; Jiralerspong, Sao; Pavlick, Anne; Veeraraghavan, Jamunarani; De Angelis, Carmine; Gutierrez, Carolina; Schiff, Rachel; Hilsenbeck, Susan G; Osborne, Charles Kent
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study
2020 Buono, G.; Crispo, A.; Giuliano, M.; De Angelis, C.; Schettini, F.; Forestieri, V.; Lauria, R.; De Laurentiis, M.; De Placido, P.; Rea, C. G.; Pacilio, C.; Esposito, E.; Grimaldi, M.; Nocerino, F.; Porciello, G.; Giudice, A.; Amore, A.; Minopoli, A.; Botti, G.; De Placido, S.; Trivedi, M. V.; Arpino, G.
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
2020 Prat, Aleix; Pascual, Tomás; De Angelis, Carmine; Gutierrez, Carolina; Llombart-Cussac, Antonio; Wang, Tao; Cortés, Javier; Rexer, Brent; Paré, Laia; Forero, Andres; Wolff, Antonio C; Morales, Serafín; Adamo, Barbara; Brasó-Maristany, Fara; Vidal, Maria; Veeraraghavan, Jamunarani; Krop, Ian; Galván, Patricia; Pavlick, Anne C; Bermejo, Begoña; Izquierdo, Miguel; Rodrik-Outmezguine, Vanessa; Reis-Filho, Jorge S; Hilsenbeck, Susan G; Oliveira, Mafalda; Dieci, Maria Vittoria; Griguolo, Gaia; Fasani, Roberta; Nuciforo, Paolo; Parker, Joel S; Conte, Pierfranco; Schiff, Rachel; Guarneri, Valentina; Osborne, C Kent; Rimawi, Mothaffar F
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
2020 Fassl, A.; Brain, C.; Abu-Remaileh, M.; Stukan, I.; Butter, D.; Stepien, P.; Feit, A. S.; Bergholz, J.; Michowski, W.; Otto, T.; Sheng, Q.; Loo, A.; Michael, W.; Tiedt, R.; De Angelis, C.; Schiff, R.; Jiang, B.; Jovanovic, B.; Nowak, K.; Ericsson, M.; Cameron, M.; Gray, N.; Dillon, D.; Zhao, J. J.; Sabatini, D. M.; Jeselsohn, R.; Brown, M.; Polyak, K.; Sicinski, P.
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era
2020 Arpino, G.; De Angelis, C.; De Placido, P.; Pietroluongo, E.; Formisano, L.; Bianco, R.; Fiore, G.; Montella, E.; Forestieri, V.; Lauria, R.; Cardalesi, C.; Vozzella, E. A.; Iervolino, A.; Giuliano, M.; De Placido, S.
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic | 1.1 Articolo in rivista | 2022 | Fu, X.; De Angelis, C.; Schiff, R. | |
| Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients | 1.1 Articolo in rivista | 2022 | Cuomo, A.; Mercurio, V.; Varricchi, G.; Galdiero, M. R.; Rossi, F. W.; Carannante, A.; Arpino, G.; Formisano, L.; Bianco, R.; Carlomagno, C.; De Angelis, C.; Giuliano, M.; Matano, E.; Picardi, M.; Salvatore, D.; De Vita, F.; Martinelli, E.; Della Corte, C. M.; Morgillo, F.; Orditura, M.; Napolitano, S.; Troiani, T.; Tocchetti, C. G. | |
| Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer | 1.1 Articolo in rivista | 2022 | Buonaiuto, Roberto; Napolitano, Fabiana; Parola, Sara; De Placido, Pietro; Forestieri, Valeria; Pecoraro, Giovanna; Servetto, Alberto; Formisano, Luigi; Formisano, Pietro; Giuliano, Mario; Arpino, Grazia; De Placido, Sabino; De Angelis, Carmine | |
| Treatment landscape of triple-negative breast cancer — expanded options, evolving needs | 1.1 Articolo in rivista | 2022 | Bianchini, G.; De Angelis, C.; Licata, L.; Gianni, L. | |
| Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models | 1.1 Articolo in rivista | 2021 | Veeraraghavan, J.; Gutierrez, C.; Sethunath, V.; Mehravaran, S.; Giuliano, M.; Shea, M. J.; Mitchell, T.; Wang, T.; Nanda, S.; Pereira, R.; Davis, R.; Goutsouliak, K.; Qin, L.; De Angelis, C.; Diala, I.; Lalani, A. S.; Nagi, C.; Hilsenbeck, S. G.; Rimawi, M. F.; Osborne, C. K.; Schiff, R. | |
| Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] | 1.7 Commento, erratum, replica e simili | 2021 | De Angelis, C; Bruzzese, D; Bernardo, A; Baldini, E; Leo, L; Fabi, A; Gamucci, T; De Placido, P; Poggio, F; Russo, S; Forestieri, V; Lauria, R; De Santo, I; Caputo, R; Cianniello, D; Michelotti, A; Del Mastro, L; De Laurentiis, M; Giuliano, M; De Placido, S; Arpino, G | |
| Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) | 1.1 Articolo in rivista | 2021 | De Angelis, C; Bruzzese, D; Bernardo, A; Baldini, E; Leo, L; Fabi, A; Gamucci, T; De Placido, P; Poggio, F; Russo, S; Forestieri, V; Lauria, R; De Santo, I; Michelotti, A; Del Mastro, L; De Laurentiis, M; Giuliano, M; De Placido, S; Arpino, G | |
| Brca1/2 ngs somatic testing in clinical practice: a short report | 1.1 Articolo in rivista | 2021 | Pepe, F.; Pisapia, P.; Russo, G.; Nacchio, M.; Pallante, P.; Vigliar, E.; De Angelis, C.; Insabato, L.; Bellevicine, C.; De Placido, S.; Troncone, G.; Malapelle, U. | |
| A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer | 1.8 Articolo in rassegna (review) | 2021 | Servetto, A.; Napolitano, F.; De Angelis, C.; De Placido, P.; Giuliano, M.; Arpino, G.; De Placido, S.; Bianco, R.; Formisano, L. | |
| A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer | 1.1 Articolo in rivista | 2021 | Abdulkareem, N. M.; Bhat, R.; Qin, L.; Vasaikar, S.; Gopinathan, A.; Mitchell, T.; Shea, M. J.; Nanda, S.; Thangavel, H.; Zhang, B.; De Angelis, C.; Schiff, R.; Trivedi, M. V. | |
| Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer | 1.1 Articolo in rivista | 2021 | De Angelis, C.; Fu, X.; Cataldo, M. L.; Nardone, A.; Pereira, R.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Sethunath, V.; Wang, T.; Hilsenbeck, S. G.; Benelli, M.; Migliaccio, I.; Guarducci, C.; Malorni, L.; Litchfield, L. M.; Liu, J.; Donaldson, J.; Selenica, P.; Brown, D. N.; Weigelt, B.; Reis-Filho, J. S.; Park, B. H.; Hurvitz, S. A.; Slamon, D. J.; Rimawi, M. F.; Jansen, V. M.; Jeselsohn, R.; Osborne, C. K.; Schiff, R. | |
| Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie | 1.1 Articolo in rivista | 2021 | De Angelis, Carmine; Nardelli, Carmela; Concolino, Paola; Pagliuca, Martina; Setaro, Mario; De Paolis, Elisa; De Placido, Pietro; Forestieri, Valeria; Scaglione, Giovanni Luca; Ranieri, Annalisa; Lombardo, Barbara; Pastore, Lucio; De Placido, Sabino; Capoluongo, Ettore | |
| Towards personalized treatment for early stage HER2-positive breast cancer | 1.1 Articolo in rivista | 2020 | Goutsouliak, K.; Veeraraghavan, J.; Sethunath, V.; De Angelis, C.; Osborne, C. K.; Rimawi, M. F.; Schiff, R. | |
| Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy | 1.1 Articolo in rivista | 2020 | Perri, F.; Ionna, F.; Longo, F.; Della Vittoria Scarpati, G.; De Angelis, C.; Ottaiano, A.; Botti, G.; Caponigro, F. | |
| Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance | 1.1 Articolo in rivista | 2020 | Bi, M.; Zhang, Z.; Jiang, Y. -Z.; Xue, P.; Wang, H.; Lai, Z.; Fu, X.; De Angelis, C.; Gong, Y.; Gao, Z.; Ruan, J.; Jin, V. X.; Marangoni, E.; Montaudon, E.; Glass, C. K.; Li, W.; Huang, T. H. -M.; Shao, Z. -M.; Schiff, R.; Chen, L.; Liu, Z. | |
| TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer | 1.1 Articolo in rivista | 2020 | Rimawi, Mothaffar F; Niravath, Polly; Wang, Tao; Rexer, Brent N; Forero, Andres; Wolff, Antonio C; Nanda, Rita; Storniolo, Anna M; Krop, Ian; Goetz, Matthew P; Nangia, Julie R; Jiralerspong, Sao; Pavlick, Anne; Veeraraghavan, Jamunarani; De Angelis, Carmine; Gutierrez, Carolina; Schiff, Rachel; Hilsenbeck, Susan G; Osborne, Charles Kent | |
| Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study | 1.1 Articolo in rivista | 2020 | Buono, G.; Crispo, A.; Giuliano, M.; De Angelis, C.; Schettini, F.; Forestieri, V.; Lauria, R.; De Laurentiis, M.; De Placido, P.; Rea, C. G.; Pacilio, C.; Esposito, E.; Grimaldi, M.; Nocerino, F.; Porciello, G.; Giudice, A.; Amore, A.; Minopoli, A.; Botti, G.; De Placido, S.; Trivedi, M. V.; Arpino, G. | |
| HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade | 1.1 Articolo in rivista | 2020 | Prat, Aleix; Pascual, Tomás; De Angelis, Carmine; Gutierrez, Carolina; Llombart-Cussac, Antonio; Wang, Tao; Cortés, Javier; Rexer, Brent; Paré, Laia; Forero, Andres; Wolff, Antonio C; Morales, Serafín; Adamo, Barbara; Brasó-Maristany, Fara; Vidal, Maria; Veeraraghavan, Jamunarani; Krop, Ian; Galván, Patricia; Pavlick, Anne C; Bermejo, Begoña; Izquierdo, Miguel; Rodrik-Outmezguine, Vanessa; Reis-Filho, Jorge S; Hilsenbeck, Susan G; Oliveira, Mafalda; Dieci, Maria Vittoria; Griguolo, Gaia; Fasani, Roberta; Nuciforo, Paolo; Parker, Joel S; Conte, Pierfranco; Schiff, Rachel; Guarneri, Valentina; Osborne, C Kent; Rimawi, Mothaffar F | |
| Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition | 1.1 Articolo in rivista | 2020 | Fassl, A.; Brain, C.; Abu-Remaileh, M.; Stukan, I.; Butter, D.; Stepien, P.; Feit, A. S.; Bergholz, J.; Michowski, W.; Otto, T.; Sheng, Q.; Loo, A.; Michael, W.; Tiedt, R.; De Angelis, C.; Schiff, R.; Jiang, B.; Jovanovic, B.; Nowak, K.; Ericsson, M.; Cameron, M.; Gray, N.; Dillon, D.; Zhao, J. J.; Sabatini, D. M.; Jeselsohn, R.; Brown, M.; Polyak, K.; Sicinski, P. | |
| Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era | 1.1 Articolo in rivista | 2020 | Arpino, G.; De Angelis, C.; De Placido, P.; Pietroluongo, E.; Formisano, L.; Bianco, R.; Fiore, G.; Montella, E.; Forestieri, V.; Lauria, R.; Cardalesi, C.; Vozzella, E. A.; Iervolino, A.; Giuliano, M.; De Placido, S. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile